Blog

Maite Gorostegui: Our paper about Management of High-Risk Neuroblastoma in the Era of Anti-GD2 Immunotherapy

Maite Gorostegui/LinkedIn

May 5, 2024, 14:01

Maite Gorostegui: Our paper about Management of High-Risk Neuroblastoma in the Era of Anti-GD2 Immunotherapy

Maite Gorostegui, Pediatric Oncologist at Pediatric Cancer Center Barcelona, shared a post on LinkedIn:

“We just published our paper about Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
These heterogeneous group of patients with locoregional disease are at risk to be over/undertreated. To determine biology is fundamental for their prognosis. We report on patients with high risk biology and the positive impact of immunotherapy on these selected group of patients.

Hospital Sant Joan de Déu Barcelona
Jaume Mora, Cinzia Lavarino, Noelia Salvador, Lucas Krauel,Alicia Castañeda, Moira Garraus Oneca Cristina L., Juan Pablo Muñoz, Sara Perez-Jaume, Margarida Simao-Rafael, Salvador Mañe.”

Maite Gorostegui

Read further.
Source: Maite Gorostegui/LinkedIn

Alicia Castañeda Anti-GD2 Immunotherapy cancer Cinzia Lavarino High-Risk Neuroblastoma immunotherapy Jaume Mora Juan Pablo Muñoz Lucas Krauel Maite Gorostegui Margarida Simao-Rafael Moira Garraus Oneca Cristina L. Noelia Salvador OncoDaily Oncology Pediatric Cancer Center Barcelona Salvador Mañe Sara Perez-Jaume

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage